Carlomaurizio Montecucco

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/1563380/publications.pdf

Version: 2024-02-01

379 papers

13,888 citations

59 h-index 27345 106 g-index

383 all docs 383
docs citations

times ranked

383

14142 citing authors

#	Article	IF	CITATIONS
1	Treating rheumatoid arthritis to target: recommendations of an international task force. Annals of the Rheumatic Diseases, 2010, 69, 631-637.	0.5	1,711
2	Prevalence of comorbidities in rheumatoid arthritis and evaluation of their monitoring: results of an international, cross-sectional study (COMORA). Annals of the Rheumatic Diseases, 2014, 73, 62-68.	0.5	659
3	Mapping and predicting mortality from systemic sclerosis. Annals of the Rheumatic Diseases, 2017, 76, 1897-1905.	0.5	410
4	Clinical course of COVID-19 in a series of patients with chronic arthritis treated with immunosuppressive targeted therapies. Annals of the Rheumatic Diseases, 2020, 79, 667-668.	0.5	393
5	Ultrasonographic evaluation of joint involvement in early rheumatoid arthritis in clinical remission: power Doppler signal predicts short-term relapse. Rheumatology, 2009, 48, 1092-1097.	0.9	274
6	Systematic microanatomical analysis of CXCL13 and CCL21in situ production and progressive lymphoid organization in rheumatoid synovitis. European Journal of Immunology, 2005, 35, 1347-1359.	1.6	232
7	Multinational evidence-based recommendations for the diagnosis and management of gout: integrating systematic literature review and expert opinion of a broad panel of rheumatologists in the 3e initiative. Annals of the Rheumatic Diseases, 2014, 73, 328-335.	0.5	222
8	Prednisone plus Methotrexate for Polymyalgia Rheumatica. Annals of Internal Medicine, 2004, 141, 493.	2.0	204
9	Evidence for treating rheumatoid arthritis to target: results of a systematic literature search. Annals of the Rheumatic Diseases, 2010, 69, 638-643.	0.5	203
10	Prevalence of comorbidities and evaluation of their screening in spondyloarthritis: results of the international cross-sectional ASAS-COMOSPA study. Annals of the Rheumatic Diseases, 2016, 75, 1016-1023.	0.5	188
11	Recommendations for the management of mixed cryoglobulinemia syndrome in hepatitis C virus-infected patients. Autoimmunity Reviews, 2011, 10, 444-454.	2.5	186
12	Tocilizumab for Treatment of Severe COVID-19 Patients: Preliminary Results from SMAtteo COvid19 REgistry (SMACORE). Microorganisms, 2020, 8, 695.	1.6	186
13	Risk factors for a first thrombotic event in antiphospholipid antibody carriers: a prospective multicentre follow-up study. Annals of the Rheumatic Diseases, 2011, 70, 1083-1086.	0.5	178
14	Adalimumab alone and in combination with disease-modifying antirheumatic drugs for the treatment of rheumatoid arthritis in clinical practice: the Research in Active Rheumatoid Arthritis (ReAct) trial. Annals of the Rheumatic Diseases, 2007, 66, 732-739.	0.5	175
15	Positive selection in autoimmunity: Abnormal immune responses to a bacterial dnaJ antigenic determinant in patients with early rheumatoid arthritis. Nature Medicine, 1995, 1, 448-452.	15.2	168
16	Sjögren's syndrome disease damage index and disease activity index: Scoring systems for the assessment of disease damage and disease activity in Sjögren's syndrome, derived from an analysis of a cohort of Italian patients. Arthritis and Rheumatism, 2007, 56, 2223-2231.	6.7	167
17	Comparison of clinical versus ultrasoundâ€determined synovitis in juvenile idiopathic arthritis. Arthritis and Rheumatism, 2009, 61, 1497-1504.	6.7	156
18	The novel cytokine interleukin- $36l_{\pm}$ is expressed in psoriatic and rheumatoid arthritis synovium. Annals of the Rheumatic Diseases, 2013, 72, 1569-1574.	0.5	146

#	Article	IF	Citations
19	Rituximab versus tocilizumab in anti-TNF inadequate responder patients with rheumatoid arthritis (R4RA): 16-week outcomes of a stratified, biopsy-driven, multicentre, open-label, phase 4 randomised controlled trial. Lancet, The, 2021, 397, 305-317.	6.3	145
20	Autoantibody profile in rheumatoid arthritis during long-term infliximab treatment. Arthritis Research, 2004, 6, R264.	2.0	140
21	Clinical Spectrum Time Course in Anti Jo-1 Positive Antisynthetase Syndrome. Medicine (United States), 2015, 94, e1144.	0.4	133
22	Mature antigenâ€experienced T helper cells synthesize and secrete the B cell chemoattractant CXCL13 in the inflammatory environment of the rheumatoid joint. Arthritis and Rheumatism, 2008, 58, 3377-3387.	6.7	124
23	B Cells in Rheumatoid Arthritis: From Pathogenic Players to Disease Biomarkers. BioMed Research International, 2014, 2014, 1-14.	0.9	121
24	Influence of Antisynthetase Antibodies Specificities on Antisynthetase Syndrome Clinical Spectrum Time Course. Journal of Clinical Medicine, 2019, 8, 2013.	1.0	118
25	Presenting features of polymyalgia rheumatica (PMR) and rheumatoid arthritis with PMR-like onset: a prospective study. Annals of the Rheumatic Diseases, 2001, 60, 1021-1024.	0.5	114
26	High IgA rheumatoid factor levels are associated with poor clinical response to tumour necrosis factor inhibitors in rheumatoid arthritis. Annals of the Rheumatic Diseases, 2007, 66, 302-307.	0.5	114
27	Safety of tumor necrosis factor \hat{l}_{\pm} blockers in hepatitis B virus occult carriers (hepatitis B surface) Tj ETQq1 1 0.78-Research, 2010, 62, 749-754.	4314 rgBT 1.5	/Overlock 110
28	Extra-articular manifestations in 587 Italian patients with rheumatoid arthritis. Rheumatology International, 2000, 19, 213-217.	1.5	105
29	Rituximab versus tocilizumab in rheumatoid arthritis: synovial biopsy-based biomarker analysis of the phase 4 R4RA randomized trial. Nature Medicine, 2022, 28, 1256-1268.	15.2	105
30	Consensus statement on blocking the effects of interleukin-6 and in particular by interleukin-6 receptor inhibition in rheumatoid arthritis and other inflammatory conditions. Annals of the Rheumatic Diseases, 2013, 72, 482-492.	0.5	102
31	Treatment of rheumatoid arthritis with anti-TNF-alpha agents: A reappraisal. Autoimmunity Reviews, 2009, 8, 274-280.	2.5	101
32	Evaluating antirheumatic treatments using synovial biopsy: a recommendation for standardisation to be used in clinical trials. Annals of the Rheumatic Diseases, 2011, 70, 423-427.	0.5	101
33	Safety and usefulness of minor salivary gland biopsy: Retrospective analysis of 502 procedures performed at a single center. Arthritis and Rheumatism, 2008, 59, 714-720.	6.7	100
34	Rheumatoid arthritis treatment: the earlier the better to prevent joint damage. RMD Open, 2015, 1 , e000057.	1.8	98
35	Incidence of COVIDâ€19 in Patients With Rheumatic Diseases Treated With Targeted Immunosuppressive Drugs: What Can We Learn From Observational Data?. Arthritis and Rheumatology, 2020, 72, 1600-1606.	2.9	95
36	CCL21 Expression Pattern of Human Secondary Lymphoid Organ Stroma Is Conserved in Inflammatory Lesions with Lymphoid Neogenesis. American Journal of Pathology, 2007, 171, 1549-1562.	1.9	94

#	Article	IF	CITATIONS
37	Good clinical response, remission, and predictors of remission in rheumatoid arthritis patients treated with tumor necrosis factor-alpha blockers: the GISEA study. Journal of Rheumatology, 2007, 34, 1670-3.	1.0	94
38	Involvement of subchondral bone marrow in rheumatoid arthritis: Lymphoid neogenesis and in situ relationship to subchondral bone marrow osteoclast recruitment. Arthritis and Rheumatism, 2005, 52, 3448-3459.	6.7	93
39	Response to Interleukin-1 Inhibitors in 140 Italian Patients with Adult-Onset Still's Disease: A Multicentre Retrospective Observational Study. Frontiers in Pharmacology, 2017, 8, 369.	1.6	89
40	Anti-citrullinated protein antibodies and high levels of rheumatoid factor are associated with systemic bone loss in patients with early untreated rheumatoid arthritis. Arthritis Research and Therapy, 2016, 18, 226.	1.6	87
41	Ultrasound-detected synovial abnormalities are frequent in clinically inactive juvenile idiopathic arthritis, but do not predict a flare of synovitis. Annals of the Rheumatic Diseases, 2013, 72, 223-228.	0.5	85
42	COVID-19 infection in a northern-Italian cohort of systemic lupus erythematosus assessed by telemedicine. Annals of the Rheumatic Diseases, 2020, 79, 1382-1383.	0.5	84
43	Potential involvement of IL-9 and Th9 cells in the pathogenesis of rheumatoid arthritis. Rheumatology, 2015, 54, 2264-2272.	0.9	83
44	Cyclosporine in Anti-Jo1-positive Patients with Corticosteroid-refractory Interstitial Lung Disease. Journal of Rheumatology, 2013, 40, 484-492.	1.0	82
45	Tumour necrosis factor antagonist therapy and cancer development: Analysis of the LORHEN registry. Autoimmunity Reviews, 2010, 9, 175-180.	2.5	80
46	In patients with early rheumatoid arthritis, the new ACR/EULAR definition of remission identifies patients with persistent absence of functional disability and suppression of ultrasonographic synovitis. Annals of the Rheumatic Diseases, 2013, 72, 245-249.	0.5	80
47	Progressive skin fibrosis is associated with a decline in lung function and worse survival in patients with diffuse cutaneous systemic sclerosis in the European Scleroderma Trials and Research (EUSTAR) cohort. Annals of the Rheumatic Diseases, 2019, 78, 648-656.	0.5	79
48	Gout impacts on function and health-related quality of life beyond associated risk factors and medical conditions: results from the KING observational study of the Italian Society for Rheumatology (SIR). Arthritis Research and Therapy, 2013, 15, R101.	1.6	72
49	An investigation of the inflammatory cytokine and chemokine network in systemic sclerosis. Annals of the Rheumatic Diseases, 2011, 70, 1115-1121.	0.5	71
50	Treating Rheumatoid Arthritis to Target: multinational recommendations assessment questionnaire. Annals of the Rheumatic Diseases, 2011, 70, 1999-2002.	0.5	71
51	Multinational evidence-based recommendations for pain management by pharmacotherapy in inflammatory arthritis: integrating systematic literature research and expert opinion of a broad panel of rheumatologists in the 3e Initiative. Rheumatology, 2012, 51, 1416-1425.	0.9	71
52	B cells in rheumatoid arthritis. Autoimmunity Reviews, 2007, 7, 137-142.	2.5	70
53	DMARDS and infections in rheumatoid arthritis. Autoimmunity Reviews, 2008, 8, 139-143.	2.5	70
54	Comparison of Brain Natriuretic Peptide (BNP) and NT-proBNP in Screening for Pulmonary Arterial Hypertension in Patients with Systemic Sclerosis. Journal of Rheumatology, 2010, 37, 2064-2070.	1.0	68

#	Article	IF	Citations
55	Multinational evidence-based recommendations on how to investigate and follow-up undifferentiated peripheral inflammatory arthritis: integrating systematic literature research and expert opinion of a broad international panel of rheumatologists in the 3E Initiative. Annals of the Rheumatic Diseases, 2011, 70, 15-24.	0.5	68
56	Vitamin D 25OH deficiency in COVID-19 patients admitted to a tertiary referral hospital. Clinical Nutrition, 2021, 40, 2469-2472.	2.3	68
57	Comorbid Conditions in the AMICA Study Patients: Effects on the Quality of Life and Drug Prescriptions by General Practitioners and Specialists. Seminars in Arthritis and Rheumatism, 2005, 35, 31-37.	1.6	64
58	Anti-cyclic citrullinated peptide antibodies in primary Sjogren's syndrome may be associated with non-erosive synovitis. Arthritis Research and Therapy, 2008, 10, R51.	1.6	64
59	The Clinical Value of Autoantibodies in Rheumatoid Arthritis. Frontiers in Medicine, 2018, 5, 339.	1.2	64
60	Immunohistological assessment of the synovial tissue in small joints in rheumatoid arthritis: validation of a minimally invasive ultrasound-guided synovial biopsy procedure. Arthritis Research and Therapy, 2007, 9, R101.	1.6	63
61	High expression levels of the B cell chemoattractant CXCL13 in rheumatoid synovium are a marker of severe disease. Rheumatology, 2014, 53, 1886-1895.	0.9	63
62	Analysis of bronchoalveolar lavage fluid proteome from systemic sclerosis patients with or without functional, clinical and radiological signs of lung fibrosis. Arthritis Research and Therapy, 2006, 8, R160.	1.6	62
63	Risk of hepatitis B virus reactivation in rheumatoid arthritis patients undergoing biologic treatment: Extending perspective from old to newer drugs. World Journal of Hepatology, 2015, 7, 344.	0.8	61
64	Serum Jo-1 Autoantibody and Isolated Arthritis in the Antisynthetase Syndrome: Review of the Literature and Report of the Experience of AENEAS Collaborative Group. Clinical Reviews in Allergy and Immunology, 2017, 52, 71-80.	2.9	60
65	The role of minor salivary gland biopsy in the diagnosis of systemic amyloidosis: results of a prospective study in 62 patients. Amyloid: the International Journal of Experimental and Clinical Investigation: the Official Journal of the International Society of Amyloidosis, 2011, 18, 80-82.	1.4	59
66	Low-dose oral prednisone improves clinical and ultrasonographic remission rates in early rheumatoid arthritis. Results of a 12 month open-label randomized study Arthritis Research and Therapy, 2012, 14, R112.	1.6	59
67	Methotrexate and glucocorticoids, but not anticytokine therapy, impair the immunogenicity of a single dose of the BNT162b2 mRNA COVID-19 vaccine in patients with chronic inflammatory arthritis. Annals of the Rheumatic Diseases, 2021, 80, 1635-1638.	0.5	55
68	Telemedicine in rheumatology: a reliable approach beyond the pandemic. Rheumatology, 2021, 60, 366-370.	0.9	53
69	Cardiovascular Comorbidities Relate More than Others with Disease Activity in Rheumatoid Arthritis. PLoS ONE, 2016, 11, e0146991.	1.1	52
70	Patient-reported impact of spondyloarthritis on work disability and working life: the ATLANTIS survey. Arthritis Research and Therapy, 2016, 18, 78.	1.6	52
71	Transient monoarthritis and psoriatic skin lesions following COVID-19. Annals of the Rheumatic Diseases, 2023, 82, e86-e86.	0.5	52
72	Disease-related malnutrition in outpatients with systemic sclerosis. Clinical Nutrition, 2012, 31, 666-671.	2.3	50

#	Article	IF	CITATIONS
73	Stress Doppler Echocardiography in Systemic Sclerosis: Evidence for a Role in the Prediction of Pulmonary Hypertension. Arthritis and Rheumatism, 2013, 65, 2403-2411.	6.7	50
74	Follow-up standards and treatment targets in rheumatoid arthritis: results of a questionnaire at the EULAR 2008. Annals of the Rheumatic Diseases, 2010, 69, 575-578.	0.5	47
75	Serum levels of CXCL13 are associated with ultrasonographic synovitis and predict power Doppler persistence in early rheumatoid arthritis treated with non-biological disease-modifying anti-rheumatic drugs. Arthritis Research and Therapy, 2012, 14, R34.	1.6	47
76	Multilevel examination of minor salivary gland biopsy for Sjogren's syndrome significantly improves diagnostic performance of AECG classification criteria. Arthritis Research, 2005, 7, R343.	2.0	46
77	Etanercept maintains the clinical benefit achieved by infliximab in patients with rheumatoid arthritis who discontinued infliximab because of side effects. Annals of the Rheumatic Diseases, 2006, 66, 249-252.	0.5	46
78	Systemic vasculitis and pregnancy: A multicenter study on maternal and neonatal outcome of 65 prospectively followed pregnancies. Autoimmunity Reviews, 2015, 14, 686-691.	2.5	46
79	Clinical follow-up predictors of disease pattern change in anti-Jo1 positive anti-synthetase syndrome: Results from a multicenter, international and retrospective study. Autoimmunity Reviews, 2017, 16, 253-257.	2.5	46
80	Serologic Profile and Mortality Rates of Scleroderma Renal Crisis in Italy. Journal of Rheumatology, 2009, 36, 1464-1469.	1.0	45
81	Inflammatory lesions in the bone marrow of rheumatoid arthritis patients: a morphological perspective. Arthritis Research and Therapy, 2012, 14, 229.	1.6	43
82	Adult acute nonâ€lymphoblastic leukaemia: reliability and prognostic significance of pretreatment bone marrow Sâ€phase size determined by flow cytofluorometry. Scandinavian Journal of Haematology, 1986, 36, 11-17.	0.0	42
83	A genetic variation located in the promoter region of the <i>UPAR</i> (<i>CD87</i>) gene is associated with the vascular complications of systemic sclerosis. Arthritis and Rheumatism, 2011, 63, 247-256.	6.7	41
84	Calcineurin Inhibitor-Based Immunosuppression and COVID-19: Results from a Multidisciplinary Cohort of Patients in Northern Italy. Microorganisms, 2020, 8, 977.	1.6	41
85	B cells in rheumatoid arthritis. Autoimmunity Reviews, 2007, 6, 482-487.	2.5	39
86	Association of a Functional Polymorphism in the Matrix Metalloproteinase-12 Promoter Region with Systemic Sclerosis in an Italian Population. Journal of Rheumatology, 2010, 37, 1852-1857.	1.0	39
87	Use of Ultrasoundâ€Guided Small Joint Biopsy to Evaluate the Histopathologic Response to Rheumatoid Arthritis Therapy: Recommendations for Application to Clinical Trials. Arthritis and Rheumatology, 2015, 67, 2601-2610.	2.9	39
88	TNF inhibitors in rheumatoid arthritis and spondyloarthritis: Are they the same?. Autoimmunity Reviews, 2018, 17, 24-28.	2. 5	39
89	Proliferative activity of bone marrow cells in primary dysmyelopoietic (preleukemic) syndromes. Cancer, 1983, 52, 1190-1195.	2.0	38
90	Switching TNF-alpha antagonists in rheumatoid arthritis: The experience of the LORHEN registry. Autoimmunity Reviews, 2010, 9, 465-469.	2. 5	38

#	Article	IF	CITATIONS
91	Early disease control by lowâ€dose prednisone comedication may affect the quality of remission in patients with early rheumatoid arthritis. Annals of the New York Academy of Sciences, 2010, 1193, 139-145.	1.8	38
92	Synovial Tissue Heterogeneity and Peripheral Blood Biomarkers. Current Rheumatology Reports, 2011, 13, 440-448.	2.1	38
93	Clinical spectrum of anti-Jo-1-associated disease. Current Opinion in Rheumatology, 2017, 29, 612-617.	2.0	38
94	Antiphospholipid syndrome: state of the art on clinical practice guidelines. RMD Open, 2018, 4, e000785.	1.8	38
95	Long term treatment of rheumatoid arthritis with rituximab. Autoimmunity Reviews, 2009, 8, 591-594.	2.5	37
96	Impact of corticosteroids and immunosuppressive therapies on symptomatic SARS-CoV-2 infection in a large cohort of patients with chronic inflammatory arthritis. Arthritis Research and Therapy, 2020, 22, 290.	1.6	37
97	Subclinical remodelling of draining lymph node structure in early and established rheumatoid arthritis assessed by power Doppler ultrasonography. Rheumatology, 2011, 50, 1395-1400.	0.9	36
98	Prevalence and significance of previously undiagnosed rheumatic diseases in pregnancy. Annals of the Rheumatic Diseases, 2012, 71, 918-923.	0.5	36
99	Imatinib-loaded gold nanoparticles inhibit proliferation of fibroblasts and macrophages from systemic sclerosis patients and ameliorate experimental bleomycin-induced lung fibrosis. Journal of Controlled Release, 2019, 310, 198-208.	4.8	36
100	Nailfold Capillaroscopy Characteristics of Antisynthetase Syndrome and Possible Clinical Associations: Results of a Multicenter International Study. Journal of Rheumatology, 2019, 46, 279-284.	1.0	36
101	Predictive Value of Antibodies to Citrullinated Peptides and Rheumatoid Factors in Antiâ€₹NFâ€i± Treated Patients. Annals of the New York Academy of Sciences, 2007, 1109, 287-295.	1.8	35
102	Long-Term Retention Rate of Anakinra in Adult Onset Still's Disease and Predictive Factors for Treatment Response. Frontiers in Pharmacology, 2019, 10, 296.	1.6	35
103	The impact of COVID-19 on rare and complex connective tissue diseases: the experience of ERN ReCONNET. Nature Reviews Rheumatology, 2021, 17, 177-184.	3.5	35
104	The â^'670G> A polymorphism in the <i>FAS</i> gene promoter region influences the susceptibility to systemic sclerosis. Annals of the Rheumatic Diseases, 2009, 68, 584-590.	0.5	34
105	The correct prednisone starting dose in polymyalgia rheumatica is related to body weight but not to disease severity. BMC Musculoskeletal Disorders, 2011, 12, 94.	0.8	34
106	Biomarkers of Good EULAR Response to the B Cell Depletion Therapy in All Seropositive Rheumatoid Arthritis Patients: Clues for the Pathogenesis. PLoS ONE, 2012, 7, e40362.	1.1	34
107	A validation study of a new classification algorithm to identify rheumatoid arthritis using administrative health databases: case-control and cohort diagnostic accuracy studies. Results from the RECord linkage On Rheumatic Diseases study of the Italian Society for Rheumatology. BMJ Open, 2015. 5. e006029-e006029.	0.8	34
108	20 years of experience with tumour necrosis factor inhibitors: what have we learned?. Rheumatology, 2018, 57, vii5-vii10.	0.9	34

#	Article	IF	CITATIONS
109	Ultrasound halo sign as a potential monitoring tool for patients with giant cell arteritis: a prospective analysis. Annals of the Rheumatic Diseases, 2021, 80, 1475-1482.	0.5	34
110	â~238 and +489 TNF-α along with TNF-RII gene polymorphisms associate with the diffuse phenotype in patients with Systemic Sclerosis. Immunology Letters, 2005, 96, 103-108.	1.1	33
111	Is the Course of Steroid-Treated Polymyalgia Rheumatica More Severe in Women?. Annals of the New York Academy of Sciences, 2006, 1069, 315-321.	1.8	33
112	B Cell Synovitis and Clinical Phenotypes in Rheumatoid Arthritis: Relationship to Disease Stages and Drug Exposure. Arthritis and Rheumatology, 2020, 72, 714-725.	2.9	33
113	Serum prealbumin is an independent predictor of mortality in systemic sclerosis outpatients. Rheumatology, 2016, 55, 315-319.	0.9	32
114	A Multicenter Retrospective Analysis Evaluating Performance of Synovial Biopsy Techniques in Patients With Inflammatory Arthritis. Arthritis and Rheumatology, 2018, 70, 702-710.	2.9	32
115	Drug survival of the first course of anti-TNF agents in patients with rheumatoid arthritis and seronegative spondyloarthritis: analysis from the MonitorNet database. Clinical and Experimental Rheumatology, 2013, 31, 857-63.	0.4	32
116	Autoantibodies to heterogeneous nuclear ribonucleoproteins. Autoimmunity, 2005, 38, 25-32.	1.2	31
117	Impact of delayed diagnoses at the time of COVID-19: increased rate of preventable bilateral blindness in giant cell arteritis. Annals of the Rheumatic Diseases, 2020, 79, 1658-1659.	0.5	31
118	Recommendations for the use of biologic therapy in rheumatoid arthritis: update from the Italian Society for Rheumatology II. Safety. Clinical and Experimental Rheumatology, 2011, 29, S15-27.	0.4	31
119	Reduction of longâ€term disability in inflammatory polyarthritis by early and persistent suppression of joint inflammation: Results from the Norfolk Arthritis Register. Arthritis Care and Research, 2011, 63, 945-952.	1.5	30
120	Evaluation of Minimally Invasive, Ultrasound-guided Synovial Biopsy Techniques by the OMERACT Filter â€" Determining Validation Requirements. Journal of Rheumatology, 2016, 43, 208-213.	1.0	30
121	Timing of onset affects arthritis presentation pattern in antisyntethase syndrome. Clinical and Experimental Rheumatology, 2018, 36, 44-49.	0.4	30
122	Association between a stromal cell-derived factor 1 (<i>SDF-1/CXCL12</i>) gene polymorphism and microvascular disease in systemic sclerosis. Annals of the Rheumatic Diseases, 2009, 68, 408-411.	0.5	29
123	Efficacy and safety of anti-TNF agents in the Lombardy rheumatoid arthritis network (LORHEN). Reumatismo, 2011, 60, 290-5.	0.4	29
124	Flow cytometric DNA content in myelodysplastic syndromes. Cytometry, 1983, 4, 238-243.	1.8	27
125	Anticyclic Citrullinated Peptide Antibodies as Markers of Erosive Arthritis in Antisynthetase Syndrome: Table 1 Journal of Rheumatology, 2010, 37, 1967.2-1967.	1.0	27
126	The Draining Lymph Node in Rheumatoid Arthritis: Current Concepts and Research Perspectives. BioMed Research International, 2015, 2015, 1-10.	0.9	27

#	Article	IF	Citations
127	The impact of unrecognized autoimmune rheumatic diseases on the incidence of preeclampsia and fetal growth restriction: a longitudinal cohort study. BMC Pregnancy and Childbirth, 2016, 16, 313.	0.9	27
128	Identification of autoantibodies to the I protein of the heterogeneous nuclear ribonucleoprotein complex in patients with systemic sclerosis. Arthritis and Rheumatism, 1996, 39, 1669-1676.	6.7	26
129	The role of extra-corporeal membrane oxygenation (ECMO) in the treatment of diffuse alveolar haemorrhage secondary to ANCA-associated vasculitis: report of two cases and review of the literature. Rheumatology International, 2019, 39, 367-375.	1.5	26
130	Fast-Track Ultrasound Clinic for the Diagnosis of Giant Cell Arteritis Changes the Prognosis of the Disease but Not the Risk of Future Relapse. Frontiers in Medicine, 2020, 7, 589794.	1.2	26
131	Seronegative autoimmune diseases: A challenging diagnosis. Autoimmunity Reviews, 2022, 21, 103143.	2.5	26
132	Assessment of synovitis to predict bone erosions in rheumatoid arthritis. Therapeutic Advances in Musculoskeletal Disease, 2012, 4, 235-244.	1.2	25
133	"Disease knowledge index―and perspectives on reproductive issues: A nationwide study on 398 women with autoimmune rheumatic diseases. Joint Bone Spine, 2019, 86, 475-481.	0.8	25
134	Development and First Validation of a Disease Activity Score for Gout. Arthritis Care and Research, 2016, 68, 1530-1537.	1.5	24
135	Long term treatment of polymyalgia rheumatica with deflazacort Annals of the Rheumatic Diseases, 1994, 53, 331-333.	0.5	23
136	The effect of newly diagnosed undifferentiated connective tissue disease on pregnancy outcome. American Journal of Obstetrics and Gynecology, 2008, 199, 632.e1-632.e6.	0.7	23
137	Recommendations for the use of biologic therapy in rheumatoid arthritis: update from the Italian Society for Rheumatology I. Efficacy. Clinical and Experimental Rheumatology, 2011, 29, S7-14.	0.4	23
138	Prevalence of undiagnosed autoimmune rheumatic diseases in the first trimester of pregnancy. Results of a twoâ€steps strategy using a selfâ€administered questionnaire and autoantibody testing. BJOG: an International Journal of Obstetrics and Gynaecology, 2008, 115, 51-57.	1.1	22
139	Counter-regulation of regulatory T cells by autoreactive CD8+ T cells in rheumatoid arthritis. Journal of Autoimmunity, 2019, 99, 81-97.	3.0	22
140	Association between age at disease onset of anti-neutrophil cytoplasmic antibody–associated vasculitis and clinical presentation and short-term outcomes. Rheumatology, 2021, 60, 617-628.	0.9	22
141	Serum osteocalcin (bone Gla-protein) following corticosteroid therapy in postmenopausal women with rheumatoid arthritis. Comparison of the effect of prednisone and deflazacort. Clinical Rheumatology, 1988, 7, 366-371.	1.0	21
142	2-DE and LC-MS/MS for a Comparative Proteomic Analysis of BALf from Subjects with Different Subsets of Inflammatory Myopathies. Journal of Proteome Research, 2009, 8, 2331-2340.	1.8	21
143	The impact of disease extent and severity detected by quantitative ultrasound analysis in the diagnosis and outcome of giant cell arteritis. Rheumatology, 2020, 59, 2299-2307.	0.9	21
144	Significance of PR3-ANCA positivity in eosinophilic granulomatosis with polyangiitis (Churg-Strauss). Rheumatology, 2021, 60, 4355-4360.	0.9	21

#	Article	IF	CITATIONS
145	Comparison of Early vs. Delayed Anakinra Treatment in Patients With Adult Onset Still's Disease and Effect on Clinical and Laboratory Outcomes. Frontiers in Medicine, 2020, 7, 42.	1.2	21
146	Sequential vincristine, arabinosylcytosine and adriamycin in acute leukemia: Cytologic and cytokinetic studies. Cytometry, 1982, 3, 104-109.	1.8	20
147	Shrinking lung syndrome in systemic sclerosis. Arthritis and Rheumatism, 2003, 48, 2999-3000.	6.7	20
148	Clinical and electrophysiological evaluation of peripheral neuropathy in rheumatoid arthritis. Journal of the Peripheral Nervous System, 2006, 11, 174-175.	1.4	20
149	B cell autoimmunity and bone damage in rheumatoid arthritis. Reumatismo, 2016, 68, 117-125.	0.4	20
150	Celiac Disease Prevalence Is Increased in Primary Sjögren's Syndrome and Diffuse Systemic Sclerosis: Lessons from a Large Multi-Center Study. Journal of Clinical Medicine, 2019, 8, 540.	1.0	20
151	Management of adult-onset Still's disease with interleukin-1 inhibitors: evidence- and consensus-based statements by a panel of Italian experts. Arthritis Research and Therapy, 2019, 21, 275.	1.6	20
152	Connective tissue diseases and autoimmune thyroid disorders in the first trimester of pregnancy. Journal of Reproductive Immunology, 2016, 114, 32-37.	0.8	19
153	Idiopathic inflammatory myopathies: state of the art on clinical practice guidelines. RMD Open, 2019, 4, e000784.	1.8	19
154	Risk of acute arterial and venous thromboembolic events in eosinophilic granulomatosis with polyangiitis (Churg–Strauss syndrome). European Respiratory Journal, 2021, 57, 2004158.	3.1	19
155	Complete remission in plasma cell leukaemia. British Journal of Haematology, 1986, 62, 525-527.	1.2	18
156	Ultrasonographic and MRI characterisation of the palindromic phase of rheumatoid arthritis. Annals of the Rheumatic Diseases, 2012, 71, 625-626.	0.5	18
157	Glucocorticoids in Rheumatoid Arthritis. Drugs, 2013, 73, 31-43.	4.9	18
158	Performance of the 2010 Classification Criteria for Rheumatoid Arthritis: A Systematic Literature Review and a Meta-Analysis. PLoS ONE, 2013, 8, e56528.	1.1	18
159	Prospectively-followed pregnancies in patients with inflammatory arthritis taking biological drugs: an Italian multicentre study. Clinical and Experimental Rheumatology, 2015, 33, 688-93.	0.4	18
160	Cytokine profile of bronchoalveolar lavage in systemic sclerosis with interstitial lung disease: comparison with usual interstitial pneumonia. Annals of the Rheumatic Diseases, 2004, 63, 892-894.	0.5	17
161	Pulmonary arterial hypertension in antisynthetase syndrome: Comment on the article by Chatterjee and Farver. Arthritis Care and Research, 2011, 63, 633-634.	1.5	16
162	Preliminary Validation of the Digital Ulcer Clinical Assessment Score in Systemic Sclerosis. Journal of Rheumatology, 2019, 46, 603-608.	1.0	16

#	Article	IF	CITATIONS
163	Disparities in the prevalence of clinical features between systemic juvenile idiopathic arthritis and adult-onset Still's disease. Rheumatology, 2022, 61, 4124-4129.	0.9	16
164	Inflammatory myopathy in a patient with cutaneous findings of pityriasis rubra pilaris: a case of Wong?s dermatomyositis. Clinical Rheumatology, 2004, 23, 63-65.	1.0	15
165	Undiagnosed connective tissue diseases. Medicine (United States), 2016, 95, e4827.	0.4	15
166	Patients', physicians', nurses', and pharmacists' preferences on the characteristics of biologic agents used in the treatment of rheumatic diseases. Patient Preference and Adherence, 2018, Volume 12, 2153-2168.	0.8	15
167	Novel Therapies for ANCA-associated Vasculitis. Current Rheumatology Reports, 2021, 23, 38.	2.1	15
168	The Genetic, Environmental, and Immunopathological Complexity of Autoantibody-Negative Rheumatoid Arthritis. International Journal of Molecular Sciences, 2021, 22, 12386.	1.8	15
169	Cytokine profile, ferritin and multi-visceral involvement characterize macrophage activation syndrome during adult-onset Still's disease. Rheumatology, 2022, 62, 321-329.	0.9	15
170	Evaluation of EBV- and HCMV-Specific T Cell Responses in Systemic Lupus Erythematosus (SLE) Patients Using a Normalized Enzyme-Linked Immunospot (ELISPOT) Assay. Journal of Immunology Research, 2019, 2019, 1-12.	0.9	14
171	Multidisciplinary Approach in the Early Detection of Undiagnosed Connective Tissue Diseases in Patients With Interstitial Lung Disease: A Retrospective Cohort Study. Frontiers in Medicine, 2020, 7, 11.	1.2	14
172	Treating rheumatoid arthritis to target: an Italian rheumatologists' survey on the acceptance of the treat-to-target recommendations. Clinical and Experimental Rheumatology, 2014, 32, 471-6.	0.4	14
173	Remission, a Therapeutic Goal in Inflammatory Arthropathies?. Drugs, 2006, 66, 1783-1795.	4.9	13
174	A comparison between nailfold capillaroscopy patterns in adulthood in juvenile and adult-onset systemic sclerosis: A EUSTAR exploratory study. Microvascular Research, 2015, 102, 19-24.	1.1	13
175	Power Doppler ultrasonographic assessment of the joint-draining lymph node complex in rheumatoid arthritis: a prospective, proof-of-concept study on treatment with tumor necrosis factor inhibitors. Arthritis Research and Therapy, 2016, 18, 242.	1.6	13
176	Early, Incomplete, or Preclinical Autoimmune Systemic Rheumatic Diseases and Pregnancy Outcome. Arthritis and Rheumatology, 2016, 68, 2555-2562.	2.9	13
177	Allopurinal mouthwashes in methotraxate-induced stomatitis. Arthritis and Rheumatism, 1994, 37, 777-778.	6.7	12
178	Systematic review of 2008-2012 literature and update of recommendations for the use of methotrexate in rheumatic diseases, with a focus on rheumatoid arthritis. Reumatismo, 2013, 65, 207-18.	0.4	12
179	Oral Low-Dose Glucocorticoids Should Be Included in Any Recommendation for the Use of Non-Biologic and Biologic Disease-Modifying Antirheumatic Drugs in the Treatment of Rheumatoid Arthritis. NeuroImmunoModulation, 2015, 22, 104-111.	0.9	12
180	Undifferentiated connective tissue diseases and adverse pregnancy outcomes. An undervalued association?. American Journal of Reproductive Immunology, 2017, 78, e12762.	1.2	12

#	Article	IF	CITATIONS
181	Disease and treatment-related morbidity in young and elderly patients with granulomatosis with polyangiitis and microscopic polyangiitis. Seminars in Arthritis and Rheumatism, 2020, 50, 1441-1448.	1.6	12
182	Algorithm for Identification of Undifferentiated Peripheral Inflammatory Arthritis: A Multinational Collaboration Through the 3e Initiative. Journal of rheumatology Supplement, The, 2011, 87, 54-58.	2.2	11
183	A "Window of Therapeutic Opportunity―for Anti-Cytokine Therapy in Patients With Coronavirus Disease 2019. Frontiers in Immunology, 2020, 11, 572635.	2.2	11
184	Plasma cell DNA content in multiple myeloma and related paraproteinemic disorders. Relationship with clinical and cytokinetic features. European Journal of Cancer & Clinical Oncology, 1984, 20, 81-90.	0.9	10
185	Peptichemio, vincristine and prednisone versus melphalan and prednisone as induction therapy in multiple myeloma. European Journal of Cancer & Clinical Oncology, 1986, 22, 787-791.	0.9	10
186	Soluble HLA-G in pregnancies complicated by autoimmune rheumatic diseases. Journal of Reproductive Immunology, 2015, 110, 67-73.	0.8	10
187	Aging in Primary Systemic Vasculitis: Implications for Diagnosis, Clinical Manifestations, and Management. Drugs and Aging, 2019, 36, 53-63.	1.3	10
188	Correspondence on $\hat{a}\in EULAR$ December 2020 viewpoints on SARS-CoV-2 vaccination in patients with RMDs $\hat{a}\in IM$. Annals of the Rheumatic Diseases, 2021, 80, e156-e156.	0.5	10
189	Impact of immunosuppressive treatment on the immunogenicity of mRNA COVID-19 vaccine â€, in vulnerable patients with giant cell arteritis . Rheumatology, 2022, 61, 870-872.	0.9	10
190	What can we learn from treatment-induced changes in rheumatoid factor and anti-citrullinated Peptide antibodies?. Journal of Rheumatology, 2008, 35, 1903-5.	1.0	10
191	In early inflammatory polyarthritis more intensive management according to the 2010 ACR/EULAR criteria leads to higher rates of clinical remission: comparison of two cohorts treated according to different treat-to-target protocols. Clinical and Experimental Rheumatology, 2017, 35, 401-405.	0.4	10
192	Sicca Syndrome and Anti-SSA/Ro Antibodies in Patients with Suspected or Definite Multiple Sclerosis. Scandinavian Journal of Rheumatology, 1989, 18, 407-412.	0.6	9
193	Rheumatoid arthritis in beta-thalassemic trait: clinical, serologic and immunogenetic profile. Joint Bone Spine, 2004, 71, 117-120.	0.8	9
194	Autoimmunity in Thrombotic Thrombocytopenic Purpura. Seminars in Thrombosis and Hemostasis, 2005, 31, 633-640.	1.5	9
195	Pain and rheumatology: An overview of the problem. European Journal of Pain Supplements, 2009, 3, 105-109.	0.0	9
196	Effects of type II collagen epitope carbamylation and citrullination in human leucocyte antigen (HLA)-DR4+ monozygotic twins discordant for rheumatoid arthritis. Clinical and Experimental Immunology, 2016, 185, 309-319.	1.1	9
197	Dose adjustments and discontinuation in TNF inhibitors treated patients: when and how. A systematic review of literature. Rheumatology, 2018, 57, vii23-vii31.	0.9	9
198	An observational multicentre study on the efficacy and safety of assisted reproductive technologies in women with rheumatic diseases. Rheumatology Advances in Practice, 2019, 3, rkz005.	0.3	9

#	Article	IF	Citations
199	Limiting factors to Boolean remission differ between autoantibody-positive and -negative patients in early rheumatoid arthritis. Therapeutic Advances in Musculoskeletal Disease, 2021, 13, 1759720X2110118.	1.2	9
200	Serum IgG2 antibody multicomposition in systemic lupus erythematosus and lupus nephritis (Part 1): cross-sectional analysis. Rheumatology, 2021, 60, 3176-3188.	0.9	9
201	Magnetic resonance imaging of the hand in mixed connective tissue disease. Annals of the Rheumatic Diseases, 2003, 62, 380-381.	0.5	8
202	Comment on: parotid gland biopsy compared with labial biopsy in the diagnosis of patients with primary Sjogren's Syndrome. Rheumatology, 2007, 46, 1625-1625.	0.9	8
203	DIABETES INSIPIDUS IN THE PRELEUKAEMIC PHASE OF ACUTE NON‣YMPHOCYTIC LEUKAEMIA: A MONOSOMY 7â€ASSOCIATED CONDITION?. Scandinavian Journal of Haematology, 1984, 33, 326-326.	0.0	8
204	Prevalence of Ankylosing Spondylitis Disease Activity Score (ASDAS) inactive disease in a cohort of patients treated with TNF-alpha inhibitors. Modern Rheumatology, 2018, 28, 542-549.	0.9	8
205	Successful treatment with baricitinib in a patient with refractory cutaneous dermatomyositis. Rheumatology, 2020, 59, e125-e127.	0.9	8
206	Denosumab for the treatment of HIV-associated osteoporosis with fractures in a premenopausal woman. Reumatismo, 2021, 73, 54-58.	0.4	8
207	Impact of Anti-Citrullinated Protein Antibodies on Progressive Systemic Bone Mineral Density Loss in Patients With Early Rheumatoid Arthritis After Two Years of Treat-to-Target. Frontiers in Immunology, 2021, 12, 701922.	2.2	8
208	Disease-related malnutrition in systemic sclerosis: evidences and implications. Clinical and Experimental Rheumatology, 2015, 33, S190-4.	0.4	8
209	A proposal of simple calculation (ERI calculator) to predict the early response to TNF-α blockers therapy in rheumatoid arthritis. Rheumatology International, 2012, 32, 349-356.	1.5	7
210	FRIO278â€Life-Threatening Onset of Systemic Vasculitis Requiring Intensive Care Unit Admission: A Case Series. Annals of the Rheumatic Diseases, 2015, 74, 525.2-525.	0.5	7
211	Histopathology of the synovial tissue: perspectives for biomarker development in chronic inflammatory arthritides. Reumatismo, 2018, 70, 121-132.	0.4	7
212	Cobalt hip prosthesis intoxication mimicking an autoimmune disease. Joint Bone Spine, 2020, 87, 652-654.	0.8	7
213	Immunosuppressive treatments selectively affect the humoral and cellular response to SARS-CoV-2 in vaccinated patients with vasculitis. Rheumatology, 2023, 62, 726-734.	0.9	7
214	Iron status in Still's disease. Lancet, The, 1995, 345, 58-59.	6.3	6
215	Pain in arthritis. European Journal of Pain Supplements, 2009, 3, 123-127.	0.0	6
216	Increasing the threshold for patient global assessment in defining remission may have a different impact in patients with early and established rheumatoid arthritis. Annals of the Rheumatic Diseases, 2022, 81, e55-e55.	0.5	6

#	Article	IF	CITATIONS
217	Diagnostic and therapeutic challenges for patients with ANCA-associated vasculitides at the time of COVID-19. Response to: †Rituximab for granulomatosis with polyangiitis in the pandemic of COVID-19: lessons from a case with severe pneumonia' by Guilpain ⟨i⟩et al⟨/i⟩. Annals of the Rheumatic Diseases, 2021, 80, e11-e11.	0.5	6
218	Second Wave Antibodies in Autoimmune Renal Diseases: The Case of Lupus Nephritis. Journal of the American Society of Nephrology: JASN, 2021, 32, 3020-3023.	3.0	6
219	Role of placental inflammatory mediators and growth factors in patients with rheumatic diseases with a focus on systemic sclerosis. Rheumatology, 2021, 60, 3307-3316.	0.9	6
220	Impact of smoking habit on adult-onset Still's disease prognosis, findings from a multicentre observational study. Clinical Rheumatology, 2022, 41, 641-647.	1.0	6
221	Serum calprotectin as a marker of ultrasound-detected synovitis in early psoriatic and rheumatoid arthritis: results from a cross-sectional retrospective study. Clinical and Experimental Rheumatology, 2019, 37, 429-436.	0.4	6
222	Anti-Ro52 antibodies positivity in antisynthetase syndrome: a single centre cohort study. Clinical and Experimental Rheumatology, 2022, 40, 27-31.	0.4	6
223	Inflammatory correlates of the Patient Global Assessment of Disease Activity vary in relation to disease duration and autoantibody status in patients with rheumatoid arthritis. Annals of the Rheumatic Diseases, 2022, 81, 1206-1213.	0.5	6
224	Sjögren-like syndrome inK chain deficiency. Arthritis and Rheumatism, 1986, 29, 1532-1533.	6.7	5
225	The Role of the Intercellular Matrix in Dermal Calcinosis of the CRST Syndrome. American Journal of Dermatopathology, 1992, 14, 42-49.	0.3	5
226	Clinical features of ANCAâ€positive systemic lupus erythematosus: report of two cases. Scandinavian Journal of Rheumatology, 2007, 36, 74-76.	0.6	5
227	Safety of Mud-Bath Applications in Moderately Active Rheumatoid Arthritis. Journal of Musculoskeletal Pain, 2010, 18, 81-87.	0.3	5
228	Switching from Intravenous to Subcutaneous Formulation of Abatacept: Different Results in a Series of 21 Patients. Journal of Rheumatology, 2015, 42, 1993-1994.	1.0	5
229	Spinal non-Hodgkin's lymphoma mimicking a flare of disease in a patient with ankylosing spondylitis treated with anti-TNF agents: case report and review of the literature. Clinical Rheumatology, 2016, 35, 275-280.	1.0	5
230	Anti-neutrophil cytoplasmic antibody specificity determines a different clinical subset in granulomatosis with polyangiitis. Clinical and Experimental Rheumatology, 2021, 39, 107-113.	0.4	5
231	Blood biomarkers recommended for diagnosing and monitoring IgG4-related disease. Considerations from the ERN ReCONNET and collaborating partners. Clinical and Experimental Rheumatology, 2022, 40, 71-80.	0.4	5
232	Adult-onset Still's disease with elderly onset, results from a multicentre study. Clinical and Experimental Rheumatology, 2022, , .	0.4	5
233	Pulmonary thromboendarterectomy in a patient with cryoagglutinins. Journal of Cardiothoracic and Vascular Anesthesia, 2000, 14, 447-448.	0.6	4
234	Antinuclear antibodies in systemic sclerosis. Future Rheumatology, 2006, 1, 365-371.	0.2	4

#	Article	IF	CITATIONS
235	Response to: â€~Telemedicine will not keep us apart in the COVID-19 pandemic' by Perniola <i>et al</i> . Annals of the Rheumatic Diseases, 2021, 80, e49-e49.	0.5	4
236	Response to: â€~COVID-19 pandemic: an opportunity to assess the utility of telemedicine in patients with rheumatic diseases' by Lopez-Medina <i>et al</i> . Annals of the Rheumatic Diseases, 2021, 80, e51-e51.	0.5	4
237	FRIO314â€Safety of the Newer Biological Dmards, TOCILIZUMAB and Abatacept, in Rheumatoid Arthritis (RA) Patients with A History of HBV Infection: A REAL Life Experience. Annals of the Rheumatic Diseases, 2014, 73, 499.1-499.	0.5	4
238	Insights Into the Concept of Rheumatoid Arthritis Flare. Frontiers in Medicine, 2022, 9, 852220.	1.2	4
239	B cell distribution and activation-induced cytidine deaminase expression in rheumatoid synovitis: clinical and bio-molecular correlates. Annals of the Rheumatic Diseases, 2011, 70, A55-A55.	0.5	3
240	FRIO172â€Drug survival of the first course of anti-TNF agents in patients with rheumatoid arthritis and spondyloarthropathies. results from the monitornet database:. Annals of the Rheumatic Diseases, 2013, 71, 370.1-370.	0.5	3
241	Lifestyle and dietary habits of patients with gout followed in rheumatology settings. Reumatismo, 2015, 67, 138-148.	0.4	3
242	Response to:  Experience of telemedicine use in a big cohort of patients with rheumatoid arthritis during COVID-19 pandemic' by Santos-Moreno <i>et al</i> . Annals of the Rheumatic Diseases, 2021, 80, e66-e66.	0.5	3
243	Response to: â€~Increased risk for severe COVID-19 in patients with inflammatory rheumatic diseases treated with rituximab' by Schulze-Koops <i>et al</i> . Annals of the Rheumatic Diseases, 2021, 80, e68-e68.	0.5	3
244	The impact of various entities of antiphospholipid antibodies positivity on adverse pregnancy outcome. An epidemiological perspective. Journal of Reproductive Immunology, 2021, 145, 103304.	0.8	3
245	Safety of BNT162b2 mRNA COVID-19 vaccine in a cohort of elderly, immunocompromised patients with systemic vasculitis. Clinical and Experimental Rheumatology, 2021, , .	0.4	3
246	Sjögren's syndrome and other rare and complex connective tissue diseases: an intriguing liaison. Clinical and Experimental Rheumatology, 2022, 40, 103-112.	0.4	3
247	Safety of BNT162b2 mRNA COVID-19 vaccine in a cohort of elderly, immunocompromised patients with systemic vasculitis. Clinical and Experimental Rheumatology, 0, , .	0.4	3
248	Retention rate of IL-1 inhibitors in Schnitzler's syndrome. Clinical and Experimental Rheumatology, 0, ,	0.4	3
249	Personalized Therapeutic Strategies in the Management of Osteoporosis in Patients with Autoantibody-Positive Rheumatoid Arthritis. Journal of Clinical Medicine, 2022, 11, 2341.	1.0	3
250	Progressive increase in time to referral and persistently severe clinical presentation over the years in autoantibody-negative patients with rheumatoid arthritis in the setting of an early arthritis clinic. Annals of the Rheumatic Diseases, 2022, , annrheumdis-2022-22264.	0.5	3
251	Improvement of hyperinsulinemic diabetes following removal of a meningioma in werner's syndrome. A case report. Acta Diabetologica Latina, 1984, 21, 191-197.	0.2	2
252	High-degree abnormalities of nuclear DNA distribution in SIg negative acute lymphoblastic leukemia with vacuolated blasts. Cancer, 1986, 58, 2632-2639.	2.0	2

#	Article	IF	Citations
253	Autoantibody profile in thrombotic thrombocytopenic purpura. Transfusion Science, 1992, 13, 33-36.	0.6	2
254	Characterization of immunoglobulin variable regions of two human pathogenic monoclonal cryocrystalglobulins. Molecular Immunology, 2008, 45, 1519-1524.	1.0	2
255	Perivascular fibrosis and IgG4-related disease: a case report. Reumatismo, 2014, 66, 245-248.	0.4	2
256	Pneumocephalus due to granulomatosis with polyangiitis. Rheumatology, 2014, 53, 2269-2269.	0.9	2
257	ABO401â€Anxiety and Depression in Patients with Rheumatoid Arthritis Treated with Biological Drugs: Prevalence and Relationship with Disease Activity. Annals of the Rheumatic Diseases, 2015, 74, 1027.2-1027.	0.5	2
258	Scleroderma Renal Crisis: Still a Lot To Do. Journal of Rheumatology, 2019, 46, 3-4.	1.0	2
259	Efficacy of a screening strategy for the detection of rheumatic diseases in early pregnancy during COVID-19 pandemic. Lupus, 2020, 29, 1821-1823.	0.8	2
260	Controversies over hydroxychloroquine in the prevention of SARS-CoV-2 infection put rheumatologists on the frontline. RMD Open, 2020, 6, e001323.	1.8	2
261	Long-term Outcome of Children Born to Women with Autoimmune Rheumatic Diseases: A Multicentre, Nationwide Study on 299 Randomly Selected Individuals. Clinical Reviews in Allergy and Immunology, 2022, 62, 346-353.	2.9	2
262	Challenges in the diagnosis of early rheumatoid arthritis in times of COVID-19. Annals of the Rheumatic Diseases, 2021, 80, 1242-1243.	0.5	2
263	In Patients with Early Peripheral Psoriatic Arthritis Baseline C-Reactive Protein, Pain and Ultrasound-Detected Synovitis Predict Subsequent Treatment with ts/bDMARDs. A Retrospective Analysis. Journal of Clinical Medicine, 2021, 10, 2834.	1.0	2
264	Italian Basic and Applied Research. Science, 1997, 276, 1773-1776.	6.0	2
265	Updating the Italian Society for Rheumatology recommendations for biologic therapy in adult patients with inflammatory rheumatic diseases. Clinical and Experimental Rheumatology, 2011, 29, S3-6.	0.4	2
266	Early development of new cardiovascular risk factors in the systemic vasculitides. Clinical and Experimental Rheumatology, 2020, 38 Suppl 124, 126-134.	0.4	2
267	Remission and Lowâ€Disease Activity in Granulomatosis with Polyangiitis and Microscopic Polyangiitis: Prevalence and Impact on Damage Accrual. Arthritis Care and Research, 0, , .	1.5	2
268	Cytokinetic Studies in Acute Leukemia during Early Induction Therapy. Tumori, 1985, 71, 69-74.	0.6	1
269	PP2. LONG-TERM FOLLOW-UP OF POLYMYALGIA RHEUMATICA PATIENTS TREATED WITH METHOTREXATE AND STEROIDS. Rheumatology, 2005, 44, iii14-iii14.	0.9	1
270	Long-term efficacy and safety of biologics in rheumatoid arthritis. Arthritis Research and Therapy, 2012, 14, .	1.6	1

#	Article	IF	CITATIONS
271	Targeting the Immunogenetic Diseases with the Appropriate HLA Molecular Typing: Critical Appraisal on 2666 Patients Typed in One Single Centre. BioMed Research International, 2013, 2013, 1-7.	0.9	1
272	Chromosomally integrated human herpesvirus 6 in a patient with systemic lupus erythematosus. Lupus, 2013, 22, 1087-1088.	0.8	1
273	FRIOO73â€Diagnostic performance of the 2010 ACR/EULAR classification criteria for rheumatoid arthritis in a cohort of early arthritis. Annals of the Rheumatic Diseases, 2013, 71, 334.1-334.	0.5	1
274	Diffuse alveolar hemorrhage as a manifestation of Behçet disease. Reumatismo, 2013, 65, 138-41.	0.4	1
275	THU0234â€Short-Term Clinical Outcome and Ultrasonographic-Synovitis Dynamics in Rheumatoid Arthritis Patients in Dmards-Induced SDAI Remission under Drug-Free Conditions. Annals of the Rheumatic Diseases, 2014, 73, 263.1-263.	0.5	1
276	THU0253â€In Early Undifferentiated Arthritis Autoantibodies and Power Doppler Identify Patients Achieving Remission after 12 Months of Treatment. Annals of the Rheumatic Diseases, 2014, 73, 270.1-270.	0.5	1
277	FRIO291â€Clinical Spectrum Time Course in Non Anti Jo-1 Positive Antisynthetase Syndrome: Table 1. Annals of the Rheumatic Diseases, 2016, 75, 540.2-541.	0.5	1
278	SAT0087â€Serum Levels of CXCL13 Refine The Predictive Ability of Autoantibodies To Identify Unstable Remission in Early Rheumatoid Arthritis. Annals of the Rheumatic Diseases, 2016, 75, 696.3-696.	0.5	1
279	A5.14â€Serum CXCL13 is a non-invasive synovitis marker holding non-redundant information compared with acute phase reactants and autoantibodies in patients with rheumatoid arthritis. Annals of the Rheumatic Diseases, 2016, 75, A46.3-A47.	0.5	1
280	AB0569â€Does The Age at Disease Onset Influence The Clinical Presentation and Long-Term Outcome of Anca-Associated Vasculitides? Results from A Single-Centre Cohort: Table 1 Annals of the Rheumatic Diseases, 2016, 75, 1099.1-1099.	0.5	1
281	THU0099â€The 2010 classification criteria and a more aggressive treatment strategy improve clinical outcomes in seropositive but not seronegative rheumatoid arthritis. , 2017, , .		1
282	THU0268â€Prevalence and features of celiac disease in patients with systemic autoimmune diseases: results of a large multicenter study. , 2017, , .		1
283	SAT0060 Response to conventional synthetic dmards differs depending on rheumatoid factor levels in anti-citrullinated positive patients with early rheumatoid arthritis. , 2017, , .		1
284	Candidate rheumatologic treatments for COVID-19. Response to:  COVID-19 infection in a patient with FMF: does colchicine have a protective effect?' by Kobak. Annals of the Rheumatic Diseases, 2021, 80, e40-e40.	0.5	1
285	Striking abdominal aortic stenosis revealing Takayasu's arteritis. European Heart Journal Cardiovascular Imaging, 2021, 22, e152-e152.	0.5	1
286	Effect of Ionophores on Lymphocyte Cellular Metabolism. Advances in Experimental Medicine and Biology, 1982, 141, 481-489.	0.8	1
287	THU0546â€Serum CXCL13 as A Biomarker of Disease Activity and Severity in IN Rheumatoid Arthritis. Comparison with Acute Phase Reactants and the Autoantibody Profile. Annals of the Rheumatic Diseases, 2014, 73, 371.2-371.	0.5	1
288	AB0806â \in The impact of dysphagia in idiopathic inflammatory myositis: an online survey of highly-specialised centres. , 2018, , .		1

#	Article	IF	CITATIONS
289	AB0768â€Osteomyelitis complicating digital ulcers in systemic sclerosis. , 2018, , .		1
290	Evolving the comprehensive management of rheumatoid arthritis: identification of unmet needs and development of practical and educational tools. Clinical and Experimental Rheumatology, 2020, 38, 1056-1067.	0.4	1
291	Methotrexate in Italian patients wiTh Rheumatoid Arthritis (MITRA study): an observational study about the use of methotrexate in early RA patients and the adherence to the EULAR 2013 recommendations. A project of the Italian Society for Rheumatology. Clinical and Experimental Rheumatology. 2021, 39, 1077-1084.	0.4	1
292	Anti-neutrophil cytoplasmic antibody specificity determines a different clinical subset in granulomatosis with polyangiitis. Clinical and Experimental Rheumatology, 2021, 39 Suppl 129, 107-113.	0.4	1
293	Costâ \in effectiveness of the early arthritis clinic organizational model: the <code><scp>ELECTRA</scp></code> study. Arthritis Care and Research, 2022, , .	1.5	1
294	Influence of initial glucocorticoid co-medication on mortality and hospitalization in early inflammatory arthritis: an investigation by record linkage of clinical and administrative databases. Arthritis Research and Therapy, 2022, 24, .	1.6	1
295	SpÃ \otimes cificitÃ \otimes 52 kDa et 60 kDa des anti-Ro(SS-A) dans les connectivites inclassables. Revue Du Rhumatisme (Edition Francaise), 2000, 67, 197-202.	0.0	0
296	Polyarthrite rhumatoÃ ⁻ de associée à un trait bêta-thalassémique : aspect clinique, sérologique et immunogénétique. Revue Du Rhumatisme (Edition Francaise), 2004, 71, 203-207.	0.0	0
297	Title is missing!. Arthritis Research, 2005, 7, P139.	2.0	0
298	Hemocytopenias in Antiphospholipid Syndrome. , 2006, , 29-40.		0
299	Chapter 23 Glucocorticoid Therapy for Polymyalgia Rheumatica. Handbook of Systemic Autoimmune Diseases, 2008, 9, 257-263.	0.1	0
300	Association Of CR2/CD21 Polymorphisms With Systemic Sclerosis. , 2010, , .		O
301	Association between the MMP-12 gene and systemic sclerosis: role of RS2276109 functional polymorphism in the modulation of skin and pulmonary fibrosis. Annals of the Rheumatic Diseases, 2010, 69, A35-A35.	0.5	0
302	Drs. Codullo and Montecucco reply. Journal of Rheumatology, 2010, 37, 1069.1-1069.	1.0	0
303	Rheumatoid arthritis and renal light-chain deposition disease: long-term effectiveness of TNF-α blockade with etanercept. International Urology and Nephrology, 2011, 43, 909-912.	0.6	0
304	Serum levels of CXCL13 are associated with ultrasonographic synovitis and predict power doppler persistence in early rheumatoid arthritis treated with non-biological disease-modifying antirheumatic drugs. Annals of the Rheumatic Diseases, 2012, 71, A12.3-A13.	0.5	0
305	FRIO436 Is gout still the rich and dissolute men's disease? Results from the king study of the italian society for rheumatology (SIR). Annals of the Rheumatic Diseases, 2013, 71, 461.3-462.	0.5	0
306	FRIO381â€Factors associated with functional disability in patients with gout. Cross-sectional results from the king study of the italian society of rheumatology (SIR). Annals of the Rheumatic Diseases, 2013, 71, 443.1-443.	0.5	0

#	Article	IF	CITATIONS
307	OP0227â€Features and longitudinal analysis of systemic sclerosis patients with inappropriate exercise-induced increase in pulmonary artery pressure estimated by echocardiography. Annals of the Rheumatic Diseases, 2013, 71, 132.2-133.	0.5	0
308	SAT0037â€Local expression of the atypical chemokine receptor D6 in systemic sclerosis. Annals of the Rheumatic Diseases, 2013, 71, 483.2-483.	0.5	0
309	SAT0114â€Synovial B cell infiltration in relationship to diagnosis and outcome in early arthritis according to the 2010 ACR/EULAR classification criteria. Annals of the Rheumatic Diseases, 2013, 71, 508.3-509.	0.5	0
310	A10.17â€Interleukin-36î± is Expressed by Synovial Plasma Cells and Induces Cytokine Production in Human Fibroblasts. Annals of the Rheumatic Diseases, 2013, 72, A78.1-A78.	0.5	0
311	OP0190-PCâ€Prevalence and incidence of gout in italy. Analysis of a primary care database. Annals of the Rheumatic Diseases, 2013, 71, 119.1-119.	0.5	0
312	THU0348â€Adherence and effectiveness of a simple program of home-made stretching in fibromyalgia. Annals of the Rheumatic Diseases, 2013, 71, 273.2-273.	0.5	0
313	FRIOO41â€Usefulness of the Classification Criteria for RA as Guidance for Treatment Selection in an Early Arthritis Cohort: 2010 Criteria Lead to Higher Rates of Clinical Remission: Table 1. Annals of the Rheumatic Diseases, 2014, 73, 396.1-396.	0.5	0
314	THU0395â€Adult Onset Still's Disease: A Multicenter Retrospective Cohort Study of 233 Italian Patients. Annals of the Rheumatic Diseases, 2014, 73, 318.2-318.	0.5	0
315	FRI0502â€Osteoporosis and Fracture Risk in Outpatients with Systemic Sclerosis. Annals of the Rheumatic Diseases, 2014, 73, 569.1-569.	0.5	0
316	A1.13â€Ultrasound-guided assessement of axillary lymph nodes in rheumatoid arthritis: cross-sectional and prospective clinico-pathologic significance. Annals of the Rheumatic Diseases, 2014, 73, A6.1-A6.	0.5	0
317	SAT0146â€Dissecting the Impact of Comorbidities on Disease Activity in Rheumatoid Arthritis: Ancillary Analysis from the COMORA Study: Table 1 Annals of the Rheumatic Diseases, 2014, 73, 643.2-643.	0.5	0
318	FRIO344â€IL-9 and CD4+Il9+ T Lymphocytes Are over Expressed in the Synovium of Patients with Rheumatoid Arthritis, Elicited in Vitro by Citrullinated Peptide Incubation and the Abrogation of Pu.1 in Mice Interfere with the Collagen Induced Arthritis. Annals of the Rheumatic Diseases, 2014, 73, 511.3-512.	0.5	0
319	AB0525â€T-Lymphocyte Subsets and CMV and EBV DNA in Blood of SLE Patients and Kidney Transplant Recipients. Annals of the Rheumatic Diseases, 2014, 73, 980.1-980.	0.5	0
320	SAT0501â€Clinical Predictors of Functional Disability in Patients with Gout: Analysis from A Multicentre Observational Study of the Italian Society for Rheumatology:. Annals of the Rheumatic Diseases, 2014, 73, 774.1-774.	0.5	0
321	FRI0067â€Anti-Citrullinated Protein Antibodies and Generalised Bone Loss in Patients with Early Rheumatoid Arthritis: A Causal Relationship?. Annals of the Rheumatic Diseases, 2014, 73, 405.3-406.	0.5	0
322	OP0230â€Systemic Vasculitis and Pregnancy: A Multicenter Study on Maternal and Neonatal Outcome of 66 Prospectively Followed Pregnancies. Annals of the Rheumatic Diseases, 2014, 73, 149.1-149.	0.5	0
323	A8.29†Outcome and predictors of relapse in early rheumatoid arthritis patients achieving DMARDs-induced stable remission during drug-free follow-up. Annals of the Rheumatic Diseases, 2015, 74, A93.2-A93.	0.5	0
324	AB0788â€Treating Axial-Spa to Target: Prevalence of Ankylosing Spondylitis Disease Activity Score (ASDAS) Inactive Disease in a Cohort of Patients Treated with Anti-TNFα Agents. Annals of the Rheumatic Diseases, 2015, 74, 1162.2-1163.	0.5	0

#	Article	IF	CITATIONS
325	SATO435â€Undiagnosed Connective Tissue Diseases in Pulmonary Arterial Hypertension Patients: Baseline and Follow-Up Results from a PAH Referral Centre. Annals of the Rheumatic Diseases, 2015, 74, 817.2-817.	0.5	O
326	THU0120â€Prognostic Significance of Residual Autoimmune/Inflammatory Activity for Disease Relapse Upon Dmard Suspension in Patients with Early Rheumatoid Arthritis in Sustained Remission After DAS-Driven Therapy. Annals of the Rheumatic Diseases, 2015, 74, 237.3-237.	0.5	0
327	AB0263â€Clinical Onset and Squeezing Test Positivity Influence the Probability to Achieve Clinical Remission at 12 Months in Patients with Early Arthritis. Annals of the Rheumatic Diseases, 2015, 74, 979.2-980.	0.5	0
328	AB0664â€Off Label Biologic Therapy in a Cohort of Patients with Behçet Disease. Annals of the Rheumatic Diseases, 2015, 74, 1120.3-1121.	0.5	0
329	FRIO477â€Isolated Arthritis Revealing an Underlying Anti-Synthetase Syndrome: Results from a Multicentre International Study. Annals of the Rheumatic Diseases, 2015, 74, 601.1-601.	0.5	0
330	ABO426â€Biologic Spacing in Rheumatoid Arthritis Patients in Persistent Disease Activity Control: A Real Life Experience. Annals of the Rheumatic Diseases, 2015, 74, 1036.3-1037.	0.5	0
331	A5.13â€Power-doppler ultrasound assessment of the joint-draining lymph node complex in rheumatoid arthritis. Annals of the Rheumatic Diseases, 2016, 75, A46.2-A46.	0.5	0
332	SAT0540â€Power Doppler Ultrasound Imaging of The Joint-Draining Lymph Node Complex in Rheumatoid Arthritis. Annals of the Rheumatic Diseases, 2016, 75, 864.3-865.	0.5	0
333	Comparing Preferences Of Patients With Rheumatic Diseases, Of Experienced Rheumatologists, Nurses And Pharmacists Toward The Treatment Of Rheumatic Diseases With Biological Agents: Results From The Cara Study. Value in Health, 2016, 19, A353.	0.1	0
334	Patients' Preferences Toward Characteristics of Treatment with Biological Agents Differ According to Experience with their Rheumatic Disease and Treatment Received or Prescribed: Results from the Cara Study. Value in Health, 2016, 19, A542-A543.	0.1	0
335	SAT0225â€Screening for Pulmonary Arterial Hypertension in Systemic Sclerosis Patients: Single Center Real-Life Performance of The Detect Algorithm. Annals of the Rheumatic Diseases, 2016, 75, 749.4-750.	0.5	0
336	FRIO510â€Long-Term Post Partum Follow-Up of Undifferentiated Connective Tissue Diseases Newly Diagnosed during Pregnancy. Annals of the Rheumatic Diseases, 2016, 75, 623.1-623.	0.5	0
337	AB0270â€Worsening of Diagnostic Delay in Early Arthritis during The Last 10 Years: A Single Center Experience. Annals of the Rheumatic Diseases, 2016, 75, 992.1-992.	0.5	O
338	OP0022â€Targeting Fibroblastoid-like Cells by Drug Loaded Engineered Gold Nanoparticles as A Novel Approach for ILD-SSC Treatment. Annals of the Rheumatic Diseases, 2016, 75, 61.1-61.	0.5	0
339	SAT0326â€Efficacy and Safety of Autologous Platelet Lysate Eye Drops in Sjögren's Syndrome: A New Approach. Annals of the Rheumatic Diseases, 2016, 75, 785.2-785.	0.5	0
340	SAT0053â€The incident immunological status predicts drug-free disease flare in rheumatoid arthritis patients achieving stringent clinical and ultrasonographic control of the peripheral inflammatory process. , 2017, , .		0
341	OP0015â€Induction of remission and maintenance in early, aggressive rheumatoid arthritis using adalimumab in combination with methotrexate with or without short-term high-dose glucocorticoids: results of a phase iv multicenter, randomized, double blind study (clintrial.gov:) Tj ETQq1 1 0.78	84314 rgBT	∏Overlock 10
342	ABO467 \hat{a} \in Efficacy and safety of assisted reproductive technologies (ART) in rheumatic patients: a multicenter study. , 2017, , .		0

#	Article		CITATIONS
343	THU0667â€A qualitative and quantitative comparison of synovial biopsy techniques during clinical trials of inflammatory arthritis. , 2017, , .		0
344	AB0214â€Methotrexate in early rheumatoid arthritis: a single-center evaluation of clinical outcome comparing two starting treatment strategies. , 2017, , .		0
345	OP0238â€Association between age at diagnosis and clinical presentation and outcomes of anca-associated vasculitis. analysis from the dcvas study. , 2018, , .		0
346	THU0110â€Early treatment and low dose corticosteroids might decrease mortality in early arthritis: results from the record linkage of clinical and administrative databases. , 2018, , .		0
347	THU0674â€Rheumatic diseases and pregnancy: a single centre dedicated clinic experience. , 2018, , .		0
348	FRIO452â€Nailfold capillaroscopy in antisynthetase syndrome (NASCAR): results of a multicenter, international study of the american and european network of antisynthetase syndrome (AENEAS). , 2018, , .		0
349	THU0290â€DISEASE AND TREATMENT-RELATED MORBIDITY IN YOUNG AND ELDERLY PATIENTS WITH ANCA-ASSOCIATED VASCULITIS. , 2019, , .		0
350	FRI0335â€PROGNOSTIC IMPACT AND CLINICAL CHARACTERISTICS OF INTERSTITIAL PNEUMONIA WITH AUTOIMMUNE FEATURES IN A MULTIDISCIPLINARY SETTING. , 2019, , .		0
351	FRIO352â€DIFFERENCES IN ANTISYNTHETASE SYNDROME DEFINITION AND RELATED DIAGNOSTIC PERFORMANCE. A SYSTEMATIC LITERATURE REVIEW INFORMING THE NEW ACR/EULAR CLASSIFICATION CRITERIA. , 2019, , .		O
352	SATO239â€PREDICTION OF LONG-TERM EVOLUTIONARY PROFILES IN EOSINOPHILIC GRANULOMATOSIS WITH POLYANGIITIS (CHURG–STRAUSS) BASED ON BASELINE AND FOLLOW-UP CHARACTERISTICS. , 2019, , .		0
353	FRIO287â€EFFICACY OF EOSINOPHILIC GRANULOMATOSIS WITH POLYANGIITIS TREATMENTS ACCORDING TO THE TYPE OF MANIFESTATIONS BASED ON ANALYSIS OF 636 PATIENTS. , 2019, , .		0
354	THU0569â€MANAGEMENT OF ADULT-ONSET STILL'S DISEASE (AOSD) WITH IL-1 INHIBITORS: EVIDENCE- AND CONSENSUS-BASED STATEMENTS BY A PANEL OF ITALIAN EXPERTS. , 2019, , .		0
355	AB0893â€WHAT IS THE CHANCE IN AN INDIVIDUAL GOUTY PATIENTTHAT DISEASE WILL BE STILL ACTIVE IN A YEAR? PREDICTIVE MODELLING MIGHT COME TO AID. , 2019, , .		0
356	FRIO145â€FACTORS ASSOCIATED WITH NEAR REMISSION DIFFER BETWEEN AUTOANTIBODY-POSITIVE AND -NEGATIVE PATIENTS WITH EARLY RHEUMATOID ARTHRITIS TREATED WITH CONVENTIONAL SYNTHETIC DISEASE-MODIFYING ANTIRHEUMATIC DRUGS. , 2019, , .		0
357	THU0164â€THE DAS28 BASED ON THE ERYTHROCYTE SEDIMENTATION RATE MAY OVERESTIMATE DISEASE ACTIVITY IN EARLY, TREATMENT-NAÃ√E PATIENTS WITH RHEUMATOID ARTHRITIS WITH HIGH LEVELS OF RHEUMATOID FACTOR. , 2019, , .		0
358	SAT0286â€EVALUATION OF SWALLOWING ALTERATIONS IN PATIENTS WITH IDIOPATHIC INFLAMMATORY MYOPATHIES. , 2019, , .		O
359	THU0079â€AUTOANTIBODY-NEGATIVE PATIENTS, THE CUT-OFF OF SIX POINTS ACCORDING TO THE 2010 ACR/EULAR CRITERIA FOR RHEUMATOID ARTHRITIS MAY MISS A POPULATION OF SEVERE, PERSISTENT POLYARTHRITIS., 2019, , .		О
360	AB0226â€One Year Experience of A Bdmard Spacing Protocol in Real Life Rheumatoid Arthritis Patients. Annals of the Rheumatic Diseases, 2016, 75, 975.1-975.	5	0

#	Article	IF	CITATIONS
361	Efficacy of functionalized-imatinib loaded gold nanoparticles on lung fibroblastoid cells from systemic sclerosis patients. , $2016, , .$		0
362	SAT0315â€lmatinib-loaded targeted gold nanoparticles ameliorate experimental lung fibrosis induced by bleomycin. , 2017, , .		0
363	AB1099â€Counselling on family planning and contraception, and pregnancy outcome in women with rheumatic diseases: a national survey of 398 patient-reported questionnaires from 24 rheumatology centers. , 2017, , .		0
364	Imatinib-loaded gold nanoparticles ameliorate experimental lung fibrosis induced by bleomycin. , 2017, , .		0
365	AB0700 \hat{a} Is it feasible to withdraw immunosuppressive treatment in real-life patients with anca-associated vasculitis?. , 2018, , .		0
366	THU0308â€Calprotectin as a marker of disease activity in patients with new onset psoriatic and rheumatoid arthritis: correlation with ultrasonographic synovitis. , 2018, , .		0
367	FRIOO35â€Disease remission is more common but less stringent in anti-citrullinated protein antibody-positive patients with early rheumatoid arthritis treated with conventional synthetic disease modifying drugs. , 2018, , .		0
368	AB0203â€Clinical phenotype and ultrasound characteristics of rheumatoid arthritis flare after discontinuation of conventional synthetic dmards. , 2018, , .		0
369	THU0111â€Frequency and predictors of sustained remission in patients with early rheumatoid arthritis treated with conventional synthetic disease modifying drugs. , 2018, , .		0
370	SAT0491 $\hat{a}\in$ Clinical features and complications in a large international cohort of antimda5 patients: a challenge for the future. , 2018, , .		0
371	The antifibrotic effect of Imatinib loaded CD44 targeted gold nanoparticles (Im-CD44-GNP) relies on alveolar macrophage regulation. , 2018, , .		0
372	A New Era for the Early and Non-Invasive Diagnosis of Giant Cell Arteritis: The Use of Fast-Track Ultrasound in Clinical Practice. Applied Sciences (Switzerland), 2022, 12, 1621.	1.3	0
373	Adherence of Italian rheumatologists to the EULAR recommendations and outcomes in early rheumatoid arthritis patients after starting conventional DMARDs: Methotrexate in Italian patients wiTh Rheumatoid Arthritis (the MITRA study). A cohort study of the I. Clinical and Experimental Rheumatology. O	0.4	0
374	Retention rate of IL-1 inhibitors in Schnitzler's syndrome Clinical and Experimental Rheumatology, 2022, , .	0.4	0
375	Adherence of Italian rheumatologists to the EULAR recommendations and outcomes in early rheumatoid arthritis patients after starting conventional DMARDs: Methotrexate in Italian patients wiTh Rheumatoid Arthritis (the MITRA study). A cohort study of the I Clinical and Experimental Rheumatology, 2022	0.4	0
376	Blood biomarkers recommended for diagnosing and monitoring IgG4-related disease. Considerations from the ERN ReCONNET and collaborating partners Clinical and Experimental Rheumatology, 2022, , .	0.4	0
377	Anti-Ro52 antibodies positivity in antisynthetase syndrome: a single centre cohort study Clinical and Experimental Rheumatology, 2022, , .	0.4	0
378	Sj \tilde{A} ¶gren's syndrome and other rare and complex connective tissue diseases: an intriguing liaison Clinical and Experimental Rheumatology, 2022, , .	0.4	0

#	Article	IF	CITATIONS
379	No evidence of short-term impact of repeated BNT162b2 vaccination on rheumatoid arthritis homeostasis in drug-free remission. Clinical Rheumatology, 0, , .	1.0	O